Site Logo

Hello, you are using an old browser that's unsafe and no longer supported. Please consider updating your browser to a newer version, or downloading a modern browser.

Your Experienced Vaccine and Infectious Disease Partner

Tuesday, May 19, 2020

Vaccine trials have unique requirements; therefore, careful consideration must be given to the design, planning, preparation, and execution of these studies.

An HCP in a vaccine clinical trialUBC’s recent global vaccine and infectious disease experience includes 42 projects encompassing clinical trials, observational studies, registries, and safety surveillance for more than 30 indications in vaccines and infectious disease, including respiratory syncytial virus (RSV), H1N1 (swine) influenza, seasonal influenza, cytomegalovirus (CMV), Dengue fever, HIV/AIDS, community-acquired pneumonia (CAP), hospital-acquired (nosocomial) pneumonia (HAP), and upper respiratory tract infections.

Most notably, we quickly accelerated a study to collect information about the potential effects of a vaccine on developing fetuses during the H1N1 pandemic.

Our experts have authored and supported countless submissions to regulatory authorities on safety, efficacy, and value, and remain current on the latest global regulatory trends and changes. Infectious diseases and vaccines are more important than ever.

Our team is passionate about helping you meet the challenges of developing and bringing your product to market for the global community. From conducting clinical trials to meeting post-approval regulatory requirements, UBC can help guide your product on its critical path to rapid approval and beyond as a trusted vaccine and infectious disease partner.

Ensure continuity of your study and patient care during the COVID-19 health crisis, harnessing UBC’s four decades of broad infectious disease expertise. Our depth and breadth of experience provides a solid foundation for understanding the unique requirements and challenges of vaccines and infectious disease studies alongside pre- and post-approval studies and regulatory obligations.

Download Article